Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca’s anifrolumab meets primary endpoint in phase III SLE trial
Image: AstraZeneca’s anifrolumab has met primary endpoint in the phase III Tulip 2 trial of systemic lupus erythematosus. Photo: courtesy of AstraZeneca.
Image: AstraZeneca’s anifrolumab has met primary endpoint in the phase III Tulip 2 trial of systemic lupus erythematosus. Photo: courtesy of AstraZeneca.